Exelixis, Inc. (LON: 0IJO)
London
· Delayed Price · Currency is GBP · Price in USD
33.15
-3.60 (-9.80%)
Jan 22, 2025, 7:13 PM BST
Exelixis Revenue
Exelixis had revenue of $539.54M USD in the quarter ending September 30, 2024, with 14.33% growth. This brings the company's revenue in the last twelve months to $2.08B, up 17.31% year-over-year. In the year 2023, Exelixis had annual revenue of $1.83B with 13.60% growth.
Revenue (ttm)
$2.08B
Revenue Growth
+17.31%
P/S Ratio
n/a
Revenue / Employee
$1.59M
Employees
1,310
Market Cap
7.62B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.83B | 219.15M | 13.60% |
Dec 31, 2022 | 1.61B | 176.09M | 12.27% |
Dec 31, 2021 | 1.43B | 447.43M | 45.31% |
Dec 31, 2020 | 987.54M | 19.76M | 2.04% |
Dec 31, 2019 | 967.78M | 113.95M | 13.35% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 38.20B |
GSK plc | 31.31B |
Haleon | 11.24B |
Smith & Nephew | 4.46B |
ConvaTec Group | 1.74B |
Hikma Pharmaceuticals | 2.39B |
HUTCHMED (China) | 483.31M |
Oxford Nanopore Technologies | 167.75M |
Exelixis News
- 12 days ago - The Best Defensive Stocks To Hedge Against Market Uncertainty - Seeking Alpha
- 13 days ago - Exelixis: Bullish On Cabo, Not So Convinced By It's Long-Term Replacement, Zanza - Seeking Alpha
- 13 days ago - Exelixis says no FDA AdCom for Cabometyx label expansion - Seeking Alpha
- 13 days ago - Exelixis Inc (EXEL) Awaits FDA Decision on Cabozantinib for Advanced Tumors - GuruFocus
- 14 days ago - Exelixis Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors - Business Wire
- 16 days ago - Exelixis Inc (EXEL) to Present at 43rd Annual J.P. Morgan Healthcare Conference - GuruFocus
- 16 days ago - Exelixis to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025 - Business Wire
- 17 days ago - (EXEL) - Analyzing Exelixis's Short Interest - Benzinga